What's New
Front Page
All in the Family to end FTD: Colonial Electric’s Food for Thought Event Clears More than $1 Million Since Inception
AFTD Board alumnus, Steve Bellwoar, has raised more than $1 million to drive AFTD’s mission in memory…
A Conversation with a Neurologist at Denali Therapeutics
Recently, AFTD had a conversation with members of the Denali Therapeutics team, including Dr. Richard Tsai, to…
Thanks to Generosity of AFTD Ambassador, Californians Receive Crucial Financial Help
Terry Walter, an AFTD Ambassador in California and Nevada, has been a force for positive change and…
AFTD Care Partner Learning Series Webinar: Navigating the Holidays with an FTD Diagnosis
The changes brought on by an FTD diagnosis can make navigating the holidays difficult. The routine changes…
Young Caregiver Talks About Finding Support Amid FTD Journey on Dementia UK Podcast
A young FTD caregiver named Lizzie discussed the grief, uncertainty, and unexpected responsibilities she faced as she…
Advancing Hope: AFTD Staff Attend NORD Breakthrough Summit in Washington, DC
Shana Dodge, PhD, AFTD’s Director of Research Engagement and Meghan Buzby, MBA, AFTD’s Director of Advocacy and…
GemVax & KAEL Announces Results from Phase 2a Clinical Trial for PSP
South Korean biopharmaceutical company GemVax & Kael announced in late October the results from its phase 2a…
Dear HelpLine: Navigating Travel During the Holidays
Dear HelpLine, I am thinking of traveling to see family this year for the holidays, but this…
A Conversation with Alector’s Vice President of Clinical Development
Earlier this year, the biopharmaceutical company Alector announced that the U.S. Food and Drug Administration (FDA) had…
Vesper Bio Announces Successful Completion of Phase 1 Study for Potentially Disease-Modifying Treatment for FTD-GRN
Biotechnology company Vesper Bio announced in early September that the phase 1 clinical trial for its potentially…
English 
Spanish (Mexico) 
French 
German 
Swedish 
Portuguese 
Italian 
Dutch 
Danish 
Polish 
Spanish (Spain)